πŸ‡ΊπŸ‡Έ FDA
Patent

US 8592571

RNAi modulation of APOB and uses thereof

granted A61KA61K31/7105A61K31/718

Quick answer

US patent 8592571 (RNAi modulation of APOB and uses thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Nov 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/7105, A61K31/718, A61P, A61P3/00